Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer

Cell Reports Medicine(2020)10.1016/j.xcrm.2020.100007Source: DataRank Database

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer is a research paper published in Cell Reports Medicine (2020). On theSindex it has a DataRank of 5.6. It has been cited 182 times, with 100 citing works in its 1-hop citation network.

N/A

5.6DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access182 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02759835

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 11.04)OA: goldTopics (60)Linked Datasets (12)DataCite Reuse (12)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 14%Citation Network 86%

Base Score Contribution

0.781

From this paper's citation signal

Citation Network Contribution

4.8

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface
ESMO Open202111 citations5 referencesContributes 0.497
Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
JTO Clinical and Research Reports20218 citations5 referencesContributes 0.439
Oligoprogressive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules
Journal of Thoracic Oncology202010 citations6 referencesContributes 0.400
Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal MET Amplification from Aneuploidy in Diverse Advanced Cancers
Current Oncology202116 citations18 referencesContributes 0.157
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
npj Precision Oncology202142 citations35 referencesContributes 0.107

Authors (31)

Anna‐Leigh Brown ORCID,Jun S. Wei ORCID,Svetlana Pack ORCID,Christopher Trindade,Chul Kim ORCID

Live enrichment

PubMed:32483558 PMC:PMC7263628 OpenAlex:https://openalex.org/W3017413818

Intramural NIH HHS

Grant: Z99 NH999999

Takeda Pharmaceuticals U.S.A.

Celgene

Exelixis

Gilead Sciences

National Cancer Institute

Novartis

Eli Lilly and Company

Novartis Pharmaceuticals Corporation

Spectrum Pharmaceuticals

U.S. Food and Drug Administration

AbbVie

AstraZeneca

National Institutes of Health

Bristol-Myers Squibb

Clovis Oncology

Medtronic

FWCI

11.04

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttp://www.cell.com/article/S2666379120300070/pdf

publisherhttp://www.cell.com/article/S2666379120300070/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2666379120300070?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666379120300070?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.xcrm.2020.100007

Fields of Study

Lung Cancer Treatments and MutationsLung Cancer Research StudiesCholangiocarcinoma and Gallbladder Cancer StudiesAcrylamidesAdultAgedAged, 80 and overAniline CompoundsCarcinoma, Non-Small-Cell LungClonal EvolutionDrug Resistance, NeoplasmErbB ReceptorsFemaleGenetic HeterogeneityHumansLung NeoplasmsMaleMiddle AgedMutationProtein Kinase InhibitorsExome SequencingYoung AdultIndolesPyrimidines

MeSH Terms

Exome SequencingAcrylamidesAdultAgedAged, 80 and overAniline CompoundsCarcinoma, Non-Small-Cell LungFemaleHumansIndolesLung NeoplasmsMaleMiddle AgedMutationPyrimidinesGenetic HeterogeneityDrug Resistance, NeoplasmProtein Kinase InhibitorsYoung AdultClonal EvolutionErbB Receptors

Keywords

OsimertinibKRASCancer researchLung cancerAdenocarcinomaBiologySomatic evolution in cancerAcquired resistanceMutationGene duplicationMedicineCancerGeneGeneticsPathology

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

10.6084/m9.figshare.22600910.v1figshare

Additional file 1 of Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

10.6084/m9.figshare.22600910figshare

Additional file 3 of Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

10.6084/m9.figshare.22600916.v1figshare

Additional file 3 of Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

10.6084/m9.figshare.22600916figshare

Additional file 1 of Signaling dynamics in coexisting monoclonal cell subpopulations unveil mechanisms of resistance to anti-cancer compounds

10.6084/m9.figshare.26384561.v1figshare

Additional file 1 of Signaling dynamics in coexisting monoclonal cell subpopulations unveil mechanisms of resistance to anti-cancer compounds

10.6084/m9.figshare.26384561figshare

Additional file 1 of A patient-derived cell model for malignant transformation in IDH-mutant glioma

10.6084/m9.figshare.26981901.v1figshare

Additional file 1 of A patient-derived cell model for malignant transformation in IDH-mutant glioma

10.6084/m9.figshare.26981901figshare

Additional file 2 of A patient-derived cell model for malignant transformation in IDH-mutant glioma

10.6084/m9.figshare.26981907.v1figshare

Additional file 2 of A patient-derived cell model for malignant transformation in IDH-mutant glioma

10.6084/m9.figshare.26981907figshare

Additional file 1 of Flavokawain C inhibits glucose metabolism and tumor angiogenesis in nasopharyngeal carcinoma by targeting the HSP90B1/STAT3/HK2 signaling axis

10.6084/m9.figshare.26716720figshare

Additional file 1 of Flavokawain C inhibits glucose metabolism and tumor angiogenesis in nasopharyngeal carcinoma by targeting the HSP90B1/STAT3/HK2 signaling axis

10.6084/m9.figshare.26716720.v1figshare